Top

Published in:

01-08-2004

Role of Hormonal Changes in the Pathogenesis of Osteoporosis in Men

Author: S. Khosla

Published in: Calcified Tissue International | Issue 2/2004

Excerpt

An understanding of the pathogenesis of osteoporosis in men depends on a clear definition of the specific entity under consideration. Conceptually, it is useful to divide male osteoporosis into three main categories: (1) involutional (age-related) osteoporosis, (2) idiopathic osteoporosis in young and middle-aged men, and (3) secondary osteoporosis (medical diseases, drugs, and environmental factors). At the outset, it is important to recognize that the three categories are not mutually exclusive: as an extreme example, a 50-year-man with vertebral fractures (idiopathic osteoporosis) may develop superimposed age-related bone loss (involutional osteoporosis) that could be worsened by corticosteroid use for his asthma (secondary osteoporosis). Thus, the main utility of this classification is to help focus our thinking on pathogenesis, since the causal mechanism(s) are likely to differ. The following discussion focusses on the first two categories, as the third is usually related to a clearly identifiable factor known to cause bone loss. …

Smith, EP, Boyd, J, Frank, GR, Takahashi, H, Cohen, RM, Specker, B, Williams, TC, Lubahn, DB, Korach, KS 1994Estrogen resistance caused by a mutation in the estrogen-receptor gene in a manN Engl J Med33110561061CrossRefPubMed

Morishima, A, Grumbach, MM, Simpson, ER, Fisher, C, Qin, K 1995Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogensJ Clin Endocrinol Metab8036893698CrossRefPubMed

Carani, C, Qin, K, Simoni, M, Faustini-Fustini, M, Serpente, S, Boyd, J, Korach, KS, Simpson, ER 1997Effect of testosterone and estradiol in a man with aromatase deficiencyN Engl J Med3379195CrossRefPubMed

Bilezikian, JP, Morishima, A, Bell, J, Grumbach, MM 1998Increased bone mass as a result of estrogen therapy in a man with aromatase deficiencyN Engl J Med339599603CrossRefPubMed

Falahati-Nini, A, Riggs, BL, Atkinson, EJ, O’Fallon, WM, Eastell, R, Khosla, S 2000Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly menJ Clin Invest10615531560PubMed

Taxel, P, Kennedy, DG, Fall, PM, Willard, AK, Clive, JM, Raisz, LG 2001The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older menJ Clin Endocrinol Metab8628692874CrossRefPubMed

Leder, BZ, LeBlanc, KM, Schoenfeld, DA, Eastell, R, Finkelstein, JS 2003Differential effects of androgens and estrogens on bone turnover in normal menJ Clin Endocrinol Metab813204210CrossRef

Turner, RT, Wakley, GK, Hannon, KS 1990Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female ratsJ Orthop Res8612617PubMed

Khosla, S, Melton, LJ,III, Atkinson, EJ, O’Fallon, WM, Klee, GG, Riggs, BL 1998Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogenJ Clin Endocrinol Metab8322662274CrossRefPubMed

10.

Slemenda, CW, Longcope, C, Zhou, L, Hui, SL, Peacock, M, Johnston, C 1997Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgensJ Clin Invest10017551759PubMed

11.

Greendale, GA, Edelstein, S, Barrett-Connor, E 1997Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo studyJ Bone Miner Res1218331843PubMed

12.

Center, JR, Nguyen, TV, Sambrook, PN, Eisman, JA 1999Hormonal and biochemical parameters in the determination of osteoporosis in elderly menJ Clin Endocrinol Metab8436263635CrossRefPubMed

13.

Ongphiphadhanakul, B, Rajatanavin, R, Chanprasertyothin, S, Piaseau, N, Chailurkit, L 1998Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal malesClin Endocrinol49803809CrossRef

14.

Beld, AW, Jong, FH, Grobbee, DE, Pols, HAP, Lamberts, SWJ 2000Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly menJ Clin Endocrinol Metab8532763282CrossRefPubMed

15.

Amin, S, Zhang, Y, Sawin, CT, Evans, SR, Hannan, MT, Kiel, DP, Wilson, PWF, Felson, DT 2000Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham studyAnn Intern Med133951963PubMed

16.

Szulc, P, Munoz, F, Claustrat, B, Garnero, P, Marchand, F 2001Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS studyJ Clin Endocrinol Metab86192199CrossRefPubMed

17.

Khosla, S, Melton, LJ,III, Atkinson, EJ, O’Fallon, WM 2001Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly menJ Clin Endocrinol Metab8635553561CrossRefPubMed

18.

Seeman, E 2002Pathogenesis of bone fragility in women and menLancet35918411850CrossRefPubMed

19.

Pfeilshifter, J, Scheidt-Nave, C, Leidig-Bruckner, G, Woitge, WW, Blum, WF, Wuster, C, Haack, D, Ziegler, R 1996Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and womenJ Clin Endocrinol Metab8125342540CrossRefPubMed

20.

Crave, JC, Lejeune, H, Brebant, C, Baret, C, Pugeat, M 1995Differential effects of insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (HepG2) cellsJ Clin Endocrinol Metab8012831289CrossRefPubMed

21.

Bateman, TA, Zimmerman, RJ, Ayers, RA, Ferguson, VL, Chapes, SK, Simske, SJ 1998Histomorphometric, physical, and mechanical effects of spaceflight and insulin-like growth factor-I on rat long bonesBone23527535CrossRefPubMed

22.

Gillberg, P, Johansson, AG, Ljunghall, . 1999Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosisCalcif Tissue Int64209213CrossRefPubMed

23.

Legrand, E, Hedde, C, Gallois, Y, Degasne, I, Boux Casson, F, Mathieu, E, Basle, MF, Chappard, D, Audran, M 2001Osteoporosis in men: Apotential role for the sex hormone binding globulinBone299095CrossRefPubMed

24.

Evans, SF, Davie, MWJ 2002Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fractureCalcif Tissue Int70915CrossRefPubMed

25.

Carlsen, CG, Soerensen, TH, Eriksen, EF 2000Prevalence of low serum estradiol levels in male osteoporosisOsteoporosis Int11697701CrossRef

26.

Kurland, ES, Rosen, CJ, Cosman, F, McMahon, D, Chan, F, Shane, E, Lindsay, R, Dempster, D, Bilezikian, JP 1997Insulin-like growth factor-I in men with idiopathic osteoporosisJ Clin Endocrinol Metab8227992805CrossRefPubMed

27.

Kurland, ES, Chan, FKW, Rosen, CJ, Bilezekian, JP 1998Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-IJ Clin Endocrinol Metab8325762579CrossRef

28.

Rosen, CJ, Kurland, ES, Vereault, D, Adler, RA, Rackoff, PJ, Craig, WY, Witte, S, Rogers, J, Bilezikian, JP 1998Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral densityJ Clin Endocrinol Metab8322862290CrossRefPubMed

Title: Role of Hormonal Changes in the Pathogenesis of Osteoporosis in Men
Author: S. Khosla
Publication date: 01-08-2004
Publisher: Springer-Verlag
Published in: Calcified Tissue International / Issue 2/2004
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-004-0290-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2004

Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes—Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy

A Second-Stage Genome Scan for QTLs Influencing BMD Variation

Osteoporosis in Men—Consensus is Premature

The Second International Conference on Osteoporosis in Men Genova, April 3-5, 2003

Announcements

Ribavirin, but Not Interferon α-2b, is Associated with Impaired Osteoblast Proliferation and Differentiation In Vitro

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials